Inhaled Corticosteroids and the Risk of Lung Cancer in Chronic Obstructive Pulmonary Disease Patients: A Systematic Review and Meta-Analysis.

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS

ACS Applied Bio Materials Pub Date : 2022-08-21 eCollection Date: 2022-01-01 DOI:10.1155/2022/9799858

Amare Abera Tareke, Wondwosen Debebe, Addis Alem, Nebiyou Simegnew Bayileyegn, Taddese Alemu Zerfu, Andualem Mossie Ayana

{"title":"Inhaled Corticosteroids and the Risk of Lung Cancer in Chronic Obstructive Pulmonary Disease Patients: A Systematic Review and Meta-Analysis.","authors":"Amare Abera Tareke, Wondwosen Debebe, Addis Alem, Nebiyou Simegnew Bayileyegn, Taddese Alemu Zerfu, Andualem Mossie Ayana","doi":"10.1155/2022/9799858","DOIUrl":null,"url":null,"abstract":"Background: The global prevalence of chronic obstructive pulmonary disease (COPD) is increasing, and the risk of lung cancer in these patients is high. The use of inhaled corticosteroids (ICSs) in COPD patients could help to decrease potential lung cancer risk. We planned to conduct this systematic review and meta-analysis to determine the role of ICS in the risk of lung cancer among COPD patients.Methods: A comprehensive search of PubMed, Science Direct, Google Scholar, and Cochrane library and a manual search of the list of references were conducted. Studies with cohort, case-control, and randomized clinical trial designs for any ICS use reporting the incidence/hazard ratio (HR) of lung cancer were included. The random-effects model was used to pool hazard ratios. Subgroup analysis and metaregression analysis were employed. Funnel plot and Egger regression test were used to assess publication bias.Results: Combining the results of 14 observations, the pooled HR for cancer risk reduction was 0.69 (95% CI 0.59-0.79), p value ≤ 0.001. The use of ICS in COPD patients showed a 31% reduction in the risk of lung cancer. Subgroup meta-analysis showed a significant reduction in the risk of lung cancer as well.Conclusion: The use of ICS in COPD patients reduces the risk of lung cancer. The risk reduction was independent of smoking status and latency period. Future studies should focus on the optimum dose and controlling confounders like asthma.","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":" ","pages":"9799858"},"PeriodicalIF":4.6000,"publicationDate":"2022-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9420625/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2022/9799858","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The global prevalence of chronic obstructive pulmonary disease (COPD) is increasing, and the risk of lung cancer in these patients is high. The use of inhaled corticosteroids (ICSs) in COPD patients could help to decrease potential lung cancer risk. We planned to conduct this systematic review and meta-analysis to determine the role of ICS in the risk of lung cancer among COPD patients.

Methods: A comprehensive search of PubMed, Science Direct, Google Scholar, and Cochrane library and a manual search of the list of references were conducted. Studies with cohort, case-control, and randomized clinical trial designs for any ICS use reporting the incidence/hazard ratio (HR) of lung cancer were included. The random-effects model was used to pool hazard ratios. Subgroup analysis and metaregression analysis were employed. Funnel plot and Egger regression test were used to assess publication bias.

Results: Combining the results of 14 observations, the pooled HR for cancer risk reduction was 0.69 (95% CI 0.59-0.79), p value ≤ 0.001. The use of ICS in COPD patients showed a 31% reduction in the risk of lung cancer. Subgroup meta-analysis showed a significant reduction in the risk of lung cancer as well.

Conclusion: The use of ICS in COPD patients reduces the risk of lung cancer. The risk reduction was independent of smoking status and latency period. Future studies should focus on the optimum dose and controlling confounders like asthma.

Abstract Image

查看原文本刊更多论文

吸入皮质类固醇与慢性阻塞性肺病患者罹患肺癌的风险：系统回顾与元分析》。

背景：全球慢性阻塞性肺病（COPD）的发病率正在上升，这些患者罹患肺癌的风险很高。对慢性阻塞性肺病患者使用吸入性皮质类固醇（ICS）有助于降低潜在的肺癌风险。我们计划进行这项系统回顾和荟萃分析，以确定 ICS 在 COPD 患者罹患肺癌风险中的作用：我们对 PubMed、Science Direct、Google Scholar 和 Cochrane 图书馆进行了全面检索，并对参考文献列表进行了人工检索。方法：对 PubM、Science Direct、Google、Cochrane 图书馆进行了全面搜索，并手动检索了参考文献列表。纳入了采用队列、病例对照和随机临床试验设计的研究，这些研究涉及任何 ICS 的使用，并报告了肺癌的发病率/危险比（HR）。采用随机效应模型汇总危险比。采用了亚组分析和元回归分析。采用漏斗图和 Egger 回归检验来评估发表偏倚：综合14项观察结果，癌症风险降低的集合HR为0.69（95% CI 0.59-0.79），P值≤0.001。慢性阻塞性肺病患者使用 ICS 可使肺癌风险降低 31%。亚组荟萃分析显示，肺癌风险也显著降低：结论：慢性阻塞性肺病患者使用 ICS 可降低罹患肺癌的风险。结论：慢性阻塞性肺病患者使用 ICS 可降低患肺癌的风险，这种风险的降低与吸烟状况和潜伏期无关。未来的研究应侧重于最佳剂量和控制哮喘等混杂因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Applied Bio Materials Chemistry-Chemistry (all)

CiteScore

9.40

自引率

2.10%

发文量

464

期刊介绍： ACS Applied Bio Materials is an interdisciplinary journal publishing original research covering all aspects of biomaterials and biointerfaces including and beyond the traditional biosensing, biomedical and therapeutic applications. The journal is devoted to reports of new and original experimental and theoretical research of an applied nature that integrates knowledge in the areas of materials, engineering, physics, bioscience, and chemistry into important bio applications. The journal is specifically interested in work that addresses the relationship between structure and function and assesses the stability and degradation of materials under relevant environmental and biological conditions.